- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Revive Therapeutics Shares Final Results of Cannabinoid Delivery Technology Research
Revive Therapeutics announced final results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.
Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) announced final results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.
As quoted in the press release:
“The successful demonstration of the cannabinoid delivery technology is a significant milestone for Revive as it positions us to develop, partner and commercialize unique medical cannabis and pharmaceutical cannabinoid therapies in large global market opportunities such as in pain, dermatology, and wound healing while complementing our research efforts in cannabinoid treatments for liver diseases, thus solidifying Revive as a unique company offering novel product and technology solutions for the medical cannabis and pharmaceutical sectors,” said Craig Leon, Chief Executive Officer of Revive.
“I am very pleased with the outcome of the research program as we have successfully demonstrated that the delivery technology in combination with synthetic cannabidiol is able to effectively reduce inflammation and be delivered in an efficient and controlled way thus offering a novel and potentially effective therapeutic option for a broad range of indications, such as pain, that would benefit from cannabinoid therapies,” said Dr. Jess D. Reed, Professor of Animal Nutrition at the University of Wisconsin-Madison.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.